← Clinical Trials
Non-Small Cell Lung Cancer Phase 3 Time-to-Event Analysis NCT00446225

EURTAC: Complete Statistical Analysis of Erlotinib in Non-Small Cell Lung Cancer

An independent statistical analysis of the randomized phase 3 EURTAC trial comparing erlotinib with standard chemotherapy in patients with advanced non-small cell lung cancer and mutations in the TK domain of EGFR, focusing on progression-free survival and overall survival.

Trial status: Completed  ·  Enrollment: 174  ·  Start: February 15, 2007  ·  Primary completion: April 11, 2012
Scope of this record

This page separates reported trial results from statistical interpretation. The numerical trial results presented here are restricted to the statistical analyses posted in the ClinicalTrials.gov data posted on ClinicalTrials.gov for EURTAC.

Registry note: This page provides an independent statistical analysis and educational interpretation of publicly reported results. ClinicalTrials.gov provides the official trial registry record.

1. Trial at a Glance

EURTAC was a randomized, open-label, parallel phase 3 treatment trial comparing an erlotinib group with a standard chemotherapy group in non-small cell lung cancer. The registry reports 174 enrolled participants and two treatment arms. Its registered primary endpoint was progression-free survival, with overall survival posted as a secondary endpoint analysis.

174
Enrollment
Total participants
2
Arms
Erlotinib vs chemotherapy
0.42
Primary PFS HR
95% CI 0.27–0.64
0.59
OS HR
95% CI 0.36–0.99
FeatureEURTAC
Trial nameEURTAC
PhasePhase 3
ConditionNon-Small Cell Lung Cancer
DesignRandomized, parallel, unmasked
Primary purposeTreatment
Enrollment174
Primary endpointProgression Free-survival
Primary endpoint typeTime-to-event
Primary analysisLog-rank test
Primary effect measureHazard ratio
Hypothesis typeSuperiority
Trial statusCompleted
ClinicalTrials.govNCT00446225

2. Clinical Question

The statistical question is whether randomized assignment to erlotinib produces a different time-to-event outcome than assignment to standard chemotherapy in the registered trial population. The primary question is expressed through progression-free survival, defined in the registry as the time from enrollment to tumor progression or death from any cause, whichever occurs first.

Population

Patients enrolled in the EURTAC phase 3 trial for non-small cell lung cancer, with the study described as treating patients with mutations in the TK domain of EGFR.

Intervention

Erlotinib group. Erlotinib is the drug intervention identified for this treatment arm in the registry data.

Comparator

Standard chemotherapy group. The registered chemotherapy interventions include carboplatin, gemcitabine, docetaxel, and cisplatin.

Primary question

Does erlotinib improve progression-free survival relative to standard chemotherapy under a superiority hypothesis?

3. Trial Design

01
Enroll174 participants
02
RandomizeTwo parallel groups
03
TreatErlotinib or standard chemotherapy
04
FollowTime-to-event outcomes
05
AnalyzeLog-rank and hazard ratio
Allocation
Randomized.
Design model
Parallel.
Masking
None.
Primary purpose
Treatment.
ARM A · Erlotinib Group

Erlotinib

  • Erlotinib is the registered drug intervention for this group.
  • The posted primary and secondary analyses compare this group with standard chemotherapy.
ARM B · Standard Chemotherapy Group

Standard chemotherapy

  • The registry identifies carboplatin, gemcitabine, docetaxel, and cisplatin among the chemotherapy interventions.
  • The statistical analyses posted by the registry use this group as the comparator.
What the design tells us: randomization establishes the comparison between treatment assignments, while the parallel design means the two randomized groups are evaluated as distinct treatment pathways. Because masking is listed as none, this was an open-label design rather than a blinded comparison.

4. Endpoints

EndpointRegistry definition / time frameRole
Progression Free-survival The time from enrollment in the study to tumor progression or death from any cause, whichever occurs first. From the date of randomization to the date of last follow up, assessed up to 24 months. Primary
Overall Survival From the date of randomization to the date of last follow up, assessed up to 24 months. Secondary

The primary endpoint is explicitly time-to-event. This distinction is important because progression-free survival is not simply a proportion of patients who progress: each participant contributes a follow-up time, and participants who have not experienced progression or death by their last follow-up can contribute censored information.

5. Statistical Methodology

Primary analysis: log-rank test

The registry reports a log-rank analysis for the primary progression-free survival endpoint. The log-rank test is designed for comparing survival or time-to-event distributions between groups while accounting for the timing of events and censoring.

Conceptual comparison
H0: survival distributions are equal    vs    H1: they differ

For EURTAC, the registry identifies the hypothesis as superiority. The posted analysis therefore evaluates whether the randomized treatment groups differ on the time-to-event endpoint rather than testing a non-inferiority margin.

Hazard ratio

The effect measure reported for both posted analyses is the hazard ratio. A hazard ratio compares the estimated instantaneous event rates between the two groups within a time-to-event framework.

Interpretation
HR = hazard in Erlotinib Group / hazard in Standard Chemotherapy Group

An HR below 1 indicates a lower estimated instantaneous event rate in the erlotinib group relative to the standard chemotherapy group, under the model and follow-up represented by the analysis.

Confidence intervals

Each posted hazard ratio is accompanied by a two-sided 95% confidence interval. The interval describes statistical uncertainty around the estimated relative treatment effect. It does not describe the range of outcomes that individual patients will experience.

P-values

The posted analyses also include p-values. A p-value addresses compatibility of the observed data with the specified null hypothesis; it is not a measure of how large or clinically important an effect is. The hazard ratio and its confidence interval are therefore essential parts of the result.

Time-to-event analysis and censoring

For a time-to-event endpoint, not every participant necessarily experiences the event during the observation period. Kaplan-Meier estimation is the standard descriptive framework for displaying such data, while the log-rank test compares the groups and a hazard ratio provides a relative effect measure. The EURTAC ClinicalTrials.gov record report the log-rank method and hazard ratio but do not provide the underlying event-by-event data needed to reconstruct a Kaplan-Meier curve.

Educational note: a Kaplan-Meier curve should not be fabricated from a hazard ratio and confidence interval alone. A valid reconstruction requires sufficiently detailed event and censoring information or appropriately digitized source data.

6. Primary Result: Progression Free-survival

Progression Free-survival is the registered primary endpoint. The registry defines it as the time from enrollment to tumor progression or death from any cause, whichever occurs first, with the time frame specified as from randomization to last follow-up and assessed up to 24 months.

Hazard ratio for progression or death

0.42

95% CI: 0.27–0.64   ·   P = 0.0001

Comparison: Erlotinib Group vs Standard Chemotherapy Group

Primary effect estimate
Hazard ratio
0.42
Null value
1.00
Clinical Biostats interpretation

An HR of 0.42 means that the estimated instantaneous rate of progression or death in the erlotinib group was 42% of the estimated rate in the standard chemotherapy group under the time-to-event analysis. Expressed as a relative difference, this corresponds to an estimated 58% lower hazard of progression or death.

The HR does not mean that 58% of patients avoided progression, that progression-free survival increased by 58%, or that an individual patient's probability of progression or death was reduced by exactly 58%. Hazard is an instantaneous event-rate concept, not a direct probability.

The two-sided 95% CI of 0.27–0.64 describes uncertainty around the estimated HR. It remains below 1 throughout the interval, so the null value of 1 is not contained in the reported confidence interval. The interval is nevertheless not a guarantee that the true effect is any particular value within it.

The p-value of 0.0001 provides evidence against the specified null hypothesis in the reported log-rank analysis. It does not measure effect size, does not indicate the probability that the treatment is effective, and does not replace the HR or confidence interval.

Because this is a time-to-event analysis, interpretation also depends on censoring and on the assumptions underlying the hazard-ratio representation. The ClinicalTrials.gov record does not provide enough information to assess the proportional-hazards assumption directly.

7. Secondary Result: Overall Survival

Overall Survival was posted as a secondary time-to-event analysis. The registry supplies the same broad follow-up frame: from randomization to last follow-up, assessed up to 24 months.

Hazard ratio for overall survival

0.59

95% CI: 0.36–0.99   ·   P = 0.043

Comparison: Erlotinib Group vs Standard Chemotherapy Group

EndpointMethodEffect measureEstimate95% CIP-value
Progression Free-survival Log Rank Hazard ratio 0.42 0.27–0.64 0.0001
Overall Survival Log Rank Hazard ratio 0.59 0.36–0.99 0.043
Clinical Biostats interpretation

An OS HR of 0.59 means that the estimated instantaneous rate of death in the erlotinib group was 59% of that in the standard chemotherapy group under the reported time-to-event analysis. In relative terms, the estimate corresponds to approximately a 41% lower estimated hazard of death.

This does not mean that 41% of patients survived, that 41% of patients were cured, or that each patient experienced the same reduction in mortality risk. It is a relative time-to-event effect measure.

The 95% CI of 0.36–0.99 is substantially wider than the primary PFS interval, reflecting greater uncertainty around the posted OS estimate. Its upper limit is close to 1, so the estimate is compatible with a relatively broad range of effects within the reported interval.

The p-value of 0.043 is a test result, not an effect-size metric. It should be interpreted alongside the HR, confidence interval, analysis method, endpoint role, and trial design rather than in isolation.

Because overall survival is a time-to-event endpoint, censoring and the assumptions used to summarize relative hazards remain relevant. The ClinicalTrials.gov record does not provide enough detail to independently evaluate those assumptions or reconstruct the survival curve.

8. Comparing the Two Time-to-Event Results

The two posted analyses tell related but distinct statistical stories. Progression Free-survival is the registered primary endpoint and has an estimated HR of 0.42, whereas Overall Survival is a secondary endpoint with an estimated HR of 0.59.

FeatureProgression Free-survivalOverall Survival
Endpoint rolePrimarySecondary
Endpoint typeTime-to-eventTime-to-event
MethodLog RankLog Rank
Effect measureHazard ratioHazard ratio
Estimate0.420.59
95% CI0.27–0.640.36–0.99
P-value0.00010.043
HypothesisSuperioritySuperiority

The HRs should not be compared as though they were two measurements of exactly the same quantity. PFS and OS have different event definitions. For PFS, the event is tumor progression or death, whichever occurs first. For OS, the event is death. Consequently, the two hazard ratios answer different questions.

The different widths of the confidence intervals also matter. The PFS interval, 0.27–0.64, gives a more precise estimate than the OS interval, 0.36–0.99, in the statistical sense of interval width. Precision and statistical significance are related but are not interchangeable: a narrower interval can coexist with a larger p-value if the estimated effect is closer to the null.

Primary versus secondary endpoint: the registry identifies progression-free survival as the primary endpoint and overall survival as secondary. That hierarchy matters when interpreting the trial's statistical story. A secondary endpoint should not simply be relabeled as another primary endpoint because its numerical result is available.

9. What a Hazard Ratio of 0.42 Means

Relative effect

The PFS HR of 0.42 is a ratio of estimated event rates within a time-to-event framework. It indicates a lower estimated instantaneous rate of progression or death for the erlotinib group than for the standard chemotherapy group.

What it does not mean

It is not a direct probability, risk ratio, odds ratio, median difference, or absolute difference in survival. It also does not imply that every patient experiences the same relative reduction in event risk.

Confidence interval

The 95% CI of 0.27–0.64 expresses uncertainty around the estimated HR. It is more informative than the point estimate alone because it shows both the direction of the estimated effect and the range of parameter values compatible with the statistical model and data at the stated confidence level.

P-value

The p-value of 0.0001 addresses the null hypothesis tested by the reported analysis. It does not quantify the magnitude of benefit. Two studies can have identical hazard ratios but different p-values if their information levels differ.

10. Statistical Methods Explained

Why was a log-rank test used?

The registered primary endpoint is time-to-event, not a simple binary outcome. A log-rank test is appropriate for comparing the timing of events between randomized groups while incorporating follow-up and censoring. In EURTAC, the registry specifically identifies the log-rank method for both posted analyses.

What does the PFS hazard ratio of 0.42 mean?

It means the estimated instantaneous rate of progression or death in the erlotinib group was 42% of the corresponding estimated rate in the standard chemotherapy group. The complementary interpretation is an estimated 58% lower hazard. This is a relative rate interpretation, not a statement that 58% of patients avoided the event.

Why is the confidence interval important?

The point estimate alone gives only one estimate of the relative treatment effect. The 95% CI of 0.27–0.64 communicates uncertainty around that estimate. Its width provides information about precision, while its location relative to 1 helps describe compatibility with the null value for a hazard ratio.

Why is the p-value not the effect size?

The p-value depends on both the observed effect and the amount of statistical information available. A very small p-value can accompany a modest effect in a large information set, while a substantial effect can have a less extreme p-value when uncertainty is high. For that reason, the HR and CI should remain central to interpretation.

Why are PFS and OS not interchangeable?

PFS counts tumor progression or death as the first event, whereas OS concerns death. A patient can therefore contribute a PFS event without having an OS event at the same time. The two endpoints measure different aspects of the clinical time course and should be interpreted separately.

What does the OS HR of 0.59 tell us?

It estimates the relative rate of death between the randomized groups. An HR of 0.59 corresponds to an estimated 41% lower hazard of death in the erlotinib group relative to standard chemotherapy. It does not specify an absolute survival probability or tell us how long an individual patient will live.

Why does the proportional-hazards assumption matter?

A single hazard ratio is especially straightforward to interpret when the relative hazards are reasonably stable over time. If hazards vary substantially in a non-proportional way, one HR can compress a more complicated time-varying pattern into a single number. The registry-reported EURTAC registry data do not contain enough information to determine whether that assumption is adequately satisfied.

11. Statistical Interpretation of the Primary Analysis

The primary PFS analysis combines three complementary pieces of information: the estimated hazard ratio, its confidence interval, and the p-value from the log-rank analysis.

Effect size

HR 0.42 describes the estimated relative difference in the instantaneous rate of progression or death between randomized groups.

Precision

The 95% CI of 0.27–0.64 describes uncertainty around the HR estimate and remains below the null value of 1.

Hypothesis test

P = 0.0001 is the reported log-rank test result under the superiority framework.

Clinical meaning

The registry result supports a difference in the time-to-event experience between randomized groups, but the HR alone does not provide an absolute treatment benefit.

This is an important distinction in clinical-trial interpretation. A statistically strong comparison does not automatically answer every clinical question. The result establishes the statistical evidence represented by the endpoint and analysis; understanding absolute survival, patient-level benefit, toxicity, quality of life, and other considerations would require additional data.

12. Interpretation of the Overall Survival Analysis

The OS analysis has an HR of 0.59 with a two-sided 95% CI of 0.36–0.99 and a p-value of 0.043. The estimate is below the null value of 1, and the upper confidence limit is close to 1.

That combination is statistically informative because the point estimate and interval should be considered together. The point estimate suggests a lower estimated rate of death in the erlotinib group, while the interval indicates meaningful uncertainty about the exact magnitude of the relative effect.

The OS result should also be kept in its registered role as a secondary endpoint. The ClinicalTrials.gov record does not identify an endpoint hierarchy beyond the designation of PFS as primary and OS as secondary, nor do they provide a detailed multiplicity procedure. Consequently, this page does not assign an additional confirmatory interpretation to the OS p-value beyond what the registry reports.

Multiplicity caution: the ClinicalTrials.gov record identifies one primary endpoint and one secondary endpoint analysis, but they do not provide a multiplicity-adjustment procedure. Therefore, the reported P-values are reproduced as posted rather than reinterpreted as if a particular familywise error-control strategy had been documented.

13. Trial Timeline

February 15, 2007

Trial start

The EURTAC trial is recorded as starting on February 15, 2007.

Phase 3

Randomized comparative treatment study

The trial is recorded as a phase 3, randomized, parallel study with no masking and a primary purpose of treatment.

April 11, 2012

Primary completion

The registry records April 11, 2012 as the primary completion date.

Completed

Results posted

The registry record is marked completed and indicates that results and statistical analyses have been posted.

14. Safety Results

The ClinicalTrials.gov record provides serious adverse event counts by randomized treatment arm. They do not provide a more detailed breakdown of individual adverse-event types or grades.

Safety measureErlotinib GroupStandard Chemotherapy Group
Serious adverse events, affected / at risk27 / 8625 / 87
Serious adverse events: affected patients
Erlotinib Group
27/86
Standard Chemotherapy
25/87

The denominator is important. The ClinicalTrials.gov record reports 27 of 86 patients in the erlotinib group and 25 of 87 patients in the standard chemotherapy group as affected by serious adverse events. These counts should not be confused with the efficacy analysis population of 174 enrolled participants because the registry-reported safety field identifies its own affected/at-risk denominators.

The registry data do not provide enough detail here to attribute particular serious adverse events to specific drugs, characterize severity beyond the serious-adverse-event designation, or perform a formal comparative safety hypothesis test. The appropriate interpretation is therefore descriptive.

15. Analysis Populations and What Is Reported

The registry-reported EURTAC data identify enrollment of 174 participants and provide serious-adverse-event denominators of 86 and 87. They do not provide explicit definitions of an intention-to-treat population, per-protocol population, or modified analysis population.

Population / featureInformation reported
Total enrollment174
Erlotinib safety denominator86
Standard chemotherapy safety denominator87
Formal ITT definitionNot reported in the ClinicalTrials.gov record
Per-protocol definitionNot reported in the ClinicalTrials.gov record
Missing-data methodNot reported in the ClinicalTrials.gov record
Imputation methodNot reported in the ClinicalTrials.gov record

For a randomized time-to-event analysis, the treatment assignment is normally retained as the basis of the primary efficacy comparison. However, because the ClinicalTrials.gov record does not explicitly define the analysis population, this page does not assign a formal ITT label to the posted EURTAC analysis.

16. Randomization and Causal Interpretation

Randomization is one of the central statistical features of EURTAC. The registry identifies the allocation as randomized, which means treatment assignment rather than post-treatment outcome was used to create the comparison.

Randomization matters because, in expectation, it balances both measured and unmeasured prognostic factors between treatment groups. This is the foundation for interpreting a difference in outcomes as a treatment-assignment comparison rather than simply an observational association.

The fact that the trial is unmasked is also important. Without masking, knowledge of treatment assignment can potentially influence aspects of treatment administration, assessment, reporting, or other processes. The magnitude and relevance of such effects depend on the endpoint and trial procedures. For a time-to-event endpoint such as PFS, the exact mechanisms by which assessment knowledge could matter cannot be evaluated from the ClinicalTrials.gov record alone.

Randomization is not the same as perfect balance: with 174 participants, randomization does not guarantee identical baseline characteristics in every sample. Its statistical purpose is to make treatment assignment independent of prognostic factors in expectation under the randomization mechanism.

17. Missing Data, Censoring, and Follow-Up

Progression-free survival and overall survival are time-to-event outcomes, so censoring is an intrinsic part of their statistical analysis. A patient who has not experienced the relevant event by the last observed follow-up does not simply disappear from the analysis; their available follow-up contributes information up to the censoring time.

The registry-reported EURTAC data specify the primary PFS time frame as from randomization to last follow-up, assessed up to 24 months. They do not provide the individual censoring rules, reasons for censoring, missing-assessment rules, or imputation methods.

Censoring

The registry defines follow-up through a last-follow-up framework, consistent with the need to account for incomplete event observation in time-to-event analysis.

Imputation

No missing-data or imputation procedure is reported in the ClinicalTrials.gov record.

Follow-up limit

The registered endpoint time frame states that assessment was up to 24 months.

Curve reconstruction

The registry-reported summary statistics are insufficient to recreate a valid Kaplan-Meier curve.

This limitation matters because survival methods rely on assumptions about censoring. In standard analyses, censoring should not systematically depend on the unobserved event process in a way that invalidates the estimator. The ClinicalTrials.gov record does not allow that assumption to be examined directly.

18. Superiority Testing

The registry identifies the hypothesis type for both posted analyses as superiority. This means the statistical question is whether the treatment groups differ, rather than whether one treatment is no worse than another within a prespecified non-inferiority margin.

Superiority framework
H0: HR = 1    vs    H1: HR ≠ 1

For a hazard-ratio analysis, 1 is the conventional null value. The ClinicalTrials.gov record reports HR 0.42 for PFS and HR 0.59 for OS.

No non-inferiority margin is reported because the posted analyses are identified as superiority analyses. It would therefore be inappropriate to interpret these results using non-inferiority logic or to introduce a margin that is not present in the ClinicalTrials.gov record.

19. Interim Analysis, Bayesian Methods, and Multiplicity

The registry-reported EURTAC registry data do not report an interim-analysis procedure, alpha-spending method, Bayesian analysis, or detailed multiplicity-adjustment strategy.

Design topicWhat the ClinicalTrials.gov record reports
Interim analysisNot reported in the ClinicalTrials.gov record
Alpha spendingNot reported in the ClinicalTrials.gov record
Bayesian methodsNot reported in the ClinicalTrials.gov record
Non-inferiority marginNot applicable to the reported superiority hypothesis
Multiplicity adjustmentNot reported in the ClinicalTrials.gov record

This is an example of why statistical interpretation should remain tied to documented methods. It is possible to describe how a method would normally be handled, but it would not be appropriate to attribute an unreported interim boundary, Bayesian prior, or multiplicity strategy to EURTAC.

20. What the Confidence Intervals Tell Us

Primary PFS interval

The 95% CI for the PFS HR is 0.27–0.64. The interval lies below 1, consistent with the direction of the point estimate of 0.42. Its width reflects uncertainty around the estimated relative treatment effect.

Secondary OS interval

The 95% CI for the OS HR is 0.36–0.99. It also lies below 1, but its upper boundary is close to the null value. This indicates more uncertainty about the precise magnitude of the OS effect than would be suggested by the PFS point estimate alone.

A confidence interval should not be interpreted as a range containing a fixed percentage of individual patient outcomes. It is an interval estimate for a population-level parameter under the statistical model and sampling framework used to produce it.

21. Why the P-Values Should Be Read Carefully

The PFS p-value is 0.0001, while the OS p-value is 0.043. These values indicate different levels of compatibility with the respective null hypotheses under the reported log-rank analyses, but they should not be converted into probabilities that the treatment works or into measures of clinical importance.

The PFS result combines a relatively low point estimate with a confidence interval that excludes 1. The OS result has a point estimate below 1 but a confidence interval extending to 0.99. The difference illustrates why reporting only p-values can obscure important information about the estimated size and precision of treatment effects.

P = 0.0001

Reported for the primary PFS log-rank analysis. It addresses the statistical test, not the size of the HR.

P = 0.043

Reported for the secondary OS log-rank analysis. It should be interpreted in the context of the endpoint's secondary role and the documented analysis framework.

22. Important Limitations and Interpretation Issues

23. Why This Trial Matters Statistically

EURTAC is a useful teaching case because its posted results illustrate the core statistical structure of a randomized time-to-event comparison without requiring a large collection of secondary analyses. The primary endpoint is explicitly time-to-event, the analysis is identified as a log-rank test, and the effect measure is a hazard ratio with a two-sided 95% confidence interval.

ConceptHow it appears in EURTAC
RandomizationThe registry identifies the allocation as randomized.
Parallel designThe design model is recorded as parallel with two arms.
Time-to-event endpointProgression Free-survival is the registered primary endpoint.
Log-rank testUsed for the posted PFS and OS analyses.
Hazard ratioReported as the effect measure for both analyses.
Confidence intervalBoth hazard ratios have two-sided 95% confidence intervals.
P-valueReported for both primary and secondary statistical analyses.
SuperiorityThe registry identifies superiority as the hypothesis type.
Endpoint hierarchyPFS is primary; OS is secondary.
CensoringRelevant because both endpoints are time-to-event measures.
Unmasked designThe masking field is listed as none.
Safety denominatorsSerious adverse events are reported as affected patients over patients at risk.

The most important statistical lesson is that the hazard ratio should never be read in isolation. A complete interpretation requires the endpoint definition, treatment comparison, analysis method, confidence interval, p-value, analysis population, and assumptions of the time-to-event model. EURTAC provides a compact example of how these pieces fit together.

24. A Practical Reading Sequence for EURTAC

A useful way to read the statistical results is to move from design to endpoint to effect estimate rather than starting with the p-value.

01
DesignRandomized, parallel, unmasked
02
EndpointPFS is primary
03
MethodLog-rank test
04
EffectHR with 95% CI
05
TestP-value

This sequence prevents a common statistical mistake: interpreting a small p-value before establishing what was actually tested. In EURTAC, the primary test concerns progression-free survival, not survival in general. The HR of 0.42 describes the relative event rate for progression or death, while the OS HR of 0.59 concerns death as a separate secondary endpoint.

25. Results Summary

MeasureErlotinib vs Standard ChemotherapyStatistical interpretation
Primary PFS HR0.42Estimated 58% lower hazard of progression or death
PFS 95% CI0.27–0.64Two-sided uncertainty interval entirely below 1
PFS P-value0.0001Reported log-rank test result
Secondary OS HR0.59Estimated 41% lower hazard of death
OS 95% CI0.36–0.99Two-sided uncertainty interval with upper limit near 1
OS P-value0.043Reported log-rank test result
Serious AEs27/86 vs 25/87Descriptive affected/at-risk counts

These are the statistical results posted on ClinicalTrials.gov for EURTAC. No median PFS, median OS, survival percentages, subgroup estimates, response rates, or additional efficacy estimates are added here because they are not contained in the ClinicalTrials.gov record.

26. Related Tutorials

Learn more about the methods used in this trial:

27. Related Calculators

28. Sources

Continue with the underlying statistical methods

Explore the survival-analysis concepts that make the EURTAC results interpretable, from Kaplan-Meier estimation and log-rank testing to hazard ratios and confidence intervals.

29. Record Summary

EURTAC is a randomized phase 3, parallel, unmasked clinical trial with 174 enrolled participants and two treatment groups: an erlotinib group and a standard chemotherapy group. Its registered primary endpoint was progression-free survival, analyzed as a time-to-event endpoint using a log-rank test and summarized with a hazard ratio.

The posted primary analysis reports a PFS HR of 0.42 with a two-sided 95% CI of 0.27–0.64 and P = 0.0001. The secondary overall-survival analysis reports an OS HR of 0.59 with a two-sided 95% CI of 0.36–0.99 and P = 0.043. These estimates indicate lower estimated event hazards in the erlotinib group under the reported analyses, while the confidence intervals quantify uncertainty around those relative effects.

The statistical interpretation should remain anchored to the endpoint definitions. PFS concerns tumor progression or death, whereas OS concerns death. Neither hazard ratio is an absolute risk measure, and neither p-value is a measure of treatment-effect magnitude. The available registry data also do not provide enough information to assess proportional hazards, reconstruct Kaplan-Meier curves, evaluate missing-data procedures, or describe an explicit multiplicity strategy.

Clinical Biostats methodology: A trial-results page should distinguish the reported statistical evidence from the educational interpretation of that evidence. For EURTAC, the most informative reading combines the randomized design, endpoint hierarchy, log-rank methodology, hazard ratios, confidence intervals, p-values, censoring considerations, and the limitations of the available registry-level data.